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contributes to epilepsy-associated depressive-like
behavior in rats with chronic temporal lobe
epilepsy
Wei Xie1,2,3*†, Lun Cai2,3,4†, Yunhong Yu5, Liang Gao3, Limin Xiao3, Qianchao He4, Zhijun Ren2 and Yuanzheng Liu2Abstract
Background: Depression has most often been diagnosed in patients with temporal lobe epilepsy (TLE), but the
mechanism underlying this association remains unclear. In this study, we report that indoleamine 2,3-dioxygenase 1
(IDO1), a rate-limiting enzyme in tryptophan metabolism, plays a key role in epilepsy-associated depressive-like behavior.
Methods: Rats which develop chronic epilepsy following pilocarpine status epilepticus exhibited a set of interictal
disorders consistent with depressive-like behavior. Changes of depressive behavior were examined by taste preference
test and forced swim test; brain IL-1β, IL-6 and IDO1 expression were quantified using real-time reverse transcriptase
PCR; brain kynurenine/tryptophan and serotonin/tryptophan ratios were analyzed by liquid chromatography-mass
spectrometry. Oral gavage of minocycline or subcutaneous injection of 1-methyltryptophan (1-MT) were used to
inhibite IDO1 expression.
Results: We observed the induction of IL-1β and IL-6 expression in rats with chronic TLE, which further induced
the upregulation of IDO1 expression in the hippocampus. The upregulation of IDO1 subsequently increased the
kynurenine/tryptophan ratio and decreased the serotonin/tryptophan ratio in the hippocampus, which contributed
to epilepsy-associated depressive-like behavior. The blockade of IDO1 activation prevented the development of
depressive-like behavior but failed to influence spontaneous seizures. This effect was achieved either indirectly,
through the anti-inflammatory tetracycline derivative minocycline, or directly, through the IDO antagonist 1-MT,
which normalizes kynurenine/tryptophan and serotonin/tryptophan ratios.
Conclusion: Brain IDO1 activity plays a key role in epileptic rats with epilepsy-associated depressive-like behavior.
Keywords: 1-methyltryptophan, Minocycline, Kynurenine, Tryptophan, Serotonin, Interleukin-1β, Interleukin-6,
Taste preference test, Forced swim test, Epilepsy, DepressionIntroduction
Depression represents one of the most common comorbid-
ities of temporal lobe epilepsy (TLE) and has a profoundly
negative impact on the quality of life of TLE patients [1].
However, the causes and mechanisms of depression in
TLE remain poorly understood. It has been reported that* Correspondence: xieweizn@fimmu.com
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unless otherwise stated.IL-6 mRNA is elevated in the brain of epileptic rats [2,3]
and IL-1β expression is also elevated in the brains [4-6] of
chronic epileptic animals and children with mesial TLE
[6]. Proinflammatory cytokines, such as IL-1β, IL-6 and
INF-γ, stimulate indoleamine 2,3-dioxygenase 1 (IDO1) in
the brain [7-9]. IDO1 is a rate-limiting enzyme in trypto-
phan (TRY) metabolism. IDO1 activity has been associated
with decreased serotonin (5-HT) content and increased
kynurenine (KYN) content and neuroplastic changes
through the effect of KYN derivatives, such as quinolinic
acid (QUIN), on glutamate receptors, which are all associ-
ated with depression [10,11]. IDO1 activation plays a key. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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has been suggested that chronic epilepsy induces the
expression of proinflammatory cytokines which, in turn,
induce IDO1 expression in the brain. The activation of
IDO1 could alter brain TRY metabolism, which contrib-
utes to epilepsy-associated depressive-like behavior in rats
with chronic TLE.
It has been reported that rats that develop chronic
epilepsy following pilocarpine status epilepticus (SE)
exhibited a set of interictal disorders consistent with de-
pression [1,12,13]. This model has been further validated
as a model of comorbidity between chronic TLE and
depression [13]. We examined this hypothesis using a




The experiments were performed using 45- to 50-day-
old male Wistar rats (Southern Medical University,
Guangzhou, People’s Republic of China). The animals
were housed and handled in strict accordance with the
guidelines of the institutional and national Committees
of Animal Use and Protection. Rats were housed in a
temperature- (23 to 25°C) and humidity- (45 to 55%)
controlled environment with a 12/12-hour modified
dark–light cycle (light on 7.00 am to 7.00 pm). The
protocol was approved through the Committee on the
Ethics of Animal Experiments of the Southern Medical
University (Permit Number: SCXK 2013–021).
Study design is outlined in Figure 1.
Status epilepticus
SE was induced as previously described [1,12,13]. Briefly,
the rats received an intraperitoneal injection of LiCl
(130 mg/kg, #310468, Sigma, Buchs, Switzerland). The
next day, the animals received a subcutaneous injection
of pilocarpine hydrochloride (40 mg/kg, #P0472, Sigma).
SE was characterized by continuous limbic seizures which
started 10 to 15 minutes after pilocarpine injection. The
severity of seizures was evaluated using the Racine [14]
scale: (i) motor arrest and twitching vibrissae; (ii) chewing,
head bobbing; (iii) forelimb clonus; (iv) forelimb clonus
and rearing; and (v) rearing and falling. Rats exhibiting
continuous generalized clonic-tonic seizures (which corre-
sponded to stages 4 to 5 on the Racine scale), lasting
at least 2 hours, were used for further studies (of 73
pilocarpine-treated rats, 66 met the requirements).
After 3 and 8 hours of seizure onset, the rats were
injected intraperitoneally with diazepam (5 mg/kg) and
phenytoin (50 mg/kg) to alleviate further seizures and
increase survival. Control animals received injections
of LiCl, diazepam, phenytoin, and saline in lieu of
pilocarpine.Monitoring spontaneous seizures
To select the proper time points for the forced swim test
(FST) and evaluate the effects of treatment on seizure
frequency in chronic TLE-induced depression, the be-
havior of the rats was continuously recorded at 3 and
6 weeks after SE using a digital camera with night vision
that could record seizures in the dark (Figure 1A). For
experiments using 1-MT (Figure 1B) or minocycline
(Figure 1C) to inhibit IDO expression from 6 weeks after
SE until the end of the experiment, the behavior of the
rats was continuously recorded. Focal seizures (motor
arrest, facial twitches and mastication), and generalized
clonic or clonic-tonic seizures (all body clonus, rearing
or rearing and falling) [1] were analyzed offline. The
spontaneous seizure counts were recorded for two con-
secutive 2-week periods: the first recording was obtained
immediately preceding 1-MT/saline or minocycline/dis-
tilled water treatment, and the second recording was ob-
tained during the 1-MT/saline or minocycline/distilled
water treatment. To analyze the data obtained from
post-SE rats treated with 1-MT/saline or minocycline/
distilled water, we compared the seizure counts before
treatment with those obtained during treatment.
Behavioral testing
We evaluated depressive behavior using two consecutive
tests: taste preference test (TPT) to examine a behavioral
correlate of anhedonia (that is, inability to experience
pleasure) [1,12,13,15], and FST to study the ability to
adapt active strategy in an inescapable stressful situation
[1,12,13,16,17]. To examine chronic TLE-induced de-
pressive behavior, we performed FST and TPT at 0, 3
and 6 weeks after SE. For experiments using 1-MT or
minocycline to inhibit IDO expression, TPT and FST
were performed at 4 days before and after treatment. To
avoid the potential immediate effects of seizures, FST
was only performed when no seizures had developed for
at least 6 hours prior to the test (determined by review-
ing video recordings).
TPT was performed using the saccharin solution con-
sumption test as previously described [1,12,13]. Briefly,
the animals had free access to a standard rodent diet.
On the first day of the experiment (habituation), each
cage was supplied with two water bottles containing
250 ml of water. The next day (test), one of the bottles
was replaced with 0.1% saccharin (#109185, Sigma) di-
luted in tap water. The test was initiated at 6.00 pm and
ran for 24 hours. TPT was expressed as a percentage of
the volume of saccharin solution intake relative to the
total water intake (saccharin plus regular water) over
24 hours. The loss of preference for saccharin is indica-
tive of anhedonia [1,12,13,15].
Subsequently, we employed a modified version of the
FST in a single 5-minute trial. This modification of the
Figure 1 Study designs. (A) Study design 1: chronic temporal lobe epilepsy induces depressive behavior. (B) Study design 2: 1-methyltryptophan
inhibits indoleamine 2,3-dioxygenase 1 directly. (C) Study design 3: minocycline inhibits indoleamine 2,3-dioxygenase 1 indirectly.1-MT,
1-methyltryptophan; 5-HT, serotonin; FST, forced swim test; IDO, indoleamine 2,3-dioxygenase; KYN, kynurenine; SE, status epilepticus; TPT,
taste preference test; TRY, tryptophan.
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depressive-like state, with the increased immobility time
indicating the state of despair [1,12,13,16,17]. Between
4.00 pm and 6.00 pm, the rat was placed for 5 minutes in
a glass container (60 cm in height and 30 cm in width)
filled with tap water to a height of 45 cm and maintained
at 22 to 25°C. The swimming behavior was videotaped
and analyzed offline by an investigator blinded to treat-
ment, and the total immobility time was calculated.
Minocycline and 1-methyltryptophan treatments
Minocycline (#M9511, Sigma) was administered at 120 mg/
kg in distilled water through gavage in a dose volume of
10 ml/kg, twice daily, at 12-hour intervals. Previous studies
have demonstrated minocycline effectively attenuated IL-1β
expression in the brain [8,18].
1-MT (#860646, Sigma) was administered through
subcutaneous injection at 50 mg/kg in a dose volume
of 5 ml/kg. The injections were administered twice
daily at 12-hour intervals, in accordance with the
methods of Professor Keith W Kelley, who had admin-
istered 50 mg/kg of 1-MT to mice twice a day, and the
effect was equal to that observed in studies using
5 mg/day pellets [8]. We prepared 1-MT using 0.1 M
NaOH and adjusted the pH to 9.0 using 1 M HCl.
Real-time reverse transcriptase PCR
Total RNA was extracted from the brain samples using
TRIzol reagent (TaKaRa Bio, Dalian, China). The reverse
transcriptase reactions were performed on a Strata-
gene Robocycler Gradient 96 Thermal Cycler (Strata-
gene, California, USA) using a reverse transcriptase kit
(TaKaRa Bio, Dalian, China) according to the manu-
facturer’s instructions. The single-stranded cDNA was
amplified through comparative quantitative real-time
reverse transcriptase PCR using a SYBR green Master Mix
kit (Thermo Scientific, California, USA; Cat. No. #K0251)
on an Mx3005 (Stratagene). The following primers were
used: β-actin, (forward) 5′-GCA GGA GTA CGA TGA
GTC CG-3′ and (reverse) 5′-ACG CAG CTC AGT AAC
AGT CC-3′; IDO1, (forward) 5′-AGC ACT GGA GAA
GGC ACT GT-3′ and (reverse) 5′-ACG TGG AAA AAG
GTG TCT GG-3′; IL-1β, (forward) 5′-AAA TGC CTC
GTG CTG TCT GAC C-3′ and (reverse) 5′-GGT GGG
TGT GCC GTC TTT CAT C-3′; and IL-6, (forward)
5′-AGC CCA CCA GGA ACG AAA G-3′ and (reverse)
5′-GGA AGG CAG TGG CTG TCA A-3′. The mRNA
expression levels of the target genes were normalized
to those of β-actin.
Liquid chromatography-mass spectrometry
Chemicals
Serotonin hydrochloride (#H9523), L-tryptophan (#PHR
1176), L-kynurenine (#K8625), and high-performanceliquid chromatography-grade methanol were purchased
from Sigma. Ultrapure water was generated using a Milli-Q
Gradient water purification system (Millipore, Molsheim,
France).Apparatus
Liquid chromatography-mass spectrometry (LC-MS) com-
prised a Prominence 20A series UFLC System (Shimadzu,
Kyoto, Japan) and an API 4000 Qtrap MS System (ABSciex,
Massachusetts, USA). The analysis was performed using
a 100 × 2.1-mm Restek C18 Aqueous column (Restek,
Pennsylvania, USA). The LC-MS detection parame-
ters and mobile phases were prepared as previously
described [19].Sample preparation
The brain samples were prepared as previously described
[20]. Briefly, the frozen brain was dissected on ice into
the different regions (prefrontal cortex, midbrain, hippo-
campus, and thalamus). The samples were subsequently
homogenized in a 10-fold volume of a 0.1 M formic acid
solution. The homogenates were centrifuged at 18,000 ×
g for 20 minute at 4°C. The supernatants were collected
and stored at −80°C until chromatographic analysis.Statistical analysis
All results were expressed as means ± SEM. The statis-
tical analysis was performed using Statistical Product
and Service Solutions (SPSS 19.0, Chicago, USA) soft-
ware (independent samples t-test, paired t-test, one-way
analysis of variance, Wilcoxon test, Mann–Whitney test
or Kruskal-Wallis test).Results
Time-dependent induction of depressive-like behavior in
chronic epileptic rats
Chronic TLE induces depressive-like behavior in rats at
6 weeks after SE, but not at 3 weeks after SE, in the FST
(Figure 2A, P < 0.01) and the TPT (Figure 2B, P < 0.01).IL-1β and IL-6 expression are induced through spontaneous
seizure in the hippocampus of rats with chronic temporal
lobe epilepsy
The IL-1β (Figure 2C, P < 0.05) mRNA levels were in-
creased at 3 weeks after SE in the seizure group but not
in the control group. At 6 weeks after SE, the difference
between IL-1β (Figure 2C, P < 0.01) and IL-6 (Figure 2D,
P < 0.01) expression was significant in the hippocampus
of rats with coexisting chronic TLE and depressive
behavior.
Figure 2 Chronic temporal lobe epilepsy-induced depressive behaviors, upregulated IL-1β, IL-6 and indoleamine 2,3-dioxygenase
expression, and altered tryptophan metabolites. (A) The duration of immobility during the forced swim test was increased in chronic
epileptic rats at 6 weeks after status epilepticus (SE) compared with the controls. (B) Saccharin consumption, calculated as a percentage of the
total fluid intake over 24 hours, was diminished at 6 weeks after SE. (C) IL-1β mRNA levels were gradually increased in chronic epileptic rats at 3
and 6 weeks after SE. (D) IL-6 mRNA levels were increased in chronic epileptic rats at 6 weeks after SE. (E) Indoleamine 2,3-dioxygenase 1 (IDO1)
mRNA levels were also upregulated in chronic epileptic rats at 3 and 6 weeks after SE. (F) IDO1 mRNA levels were primarily upregulated in the
hippocampus compared with the thalamus, midbrain and prefrontal cortex, and compared with the controls. (G) The kynurenine (KYN)/tryptophan
(TRY) ratio was elevated and (H) the serotonin (5-HT)/TRY ratio was reduced in chronic epileptic rats at 3 and 6 weeks after SE. All the data at 0 weeks
are baseline values (naive rats). Statistical significance was determined using independent samples t-test and one-way analysis of variance. The data are
presented as means ± SEM, n = 5 to 6; *P < 0.05; **P < 0.01.
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of IL-1β and IL-6 expression in the hippocampus of rats
with coexisting chronic temporal lobe epilepsy and
depressive behavior
IDO1 expression was significantly upregulated at both 3
and 6 weeks after SE (Figure 2E, P < 0.01 compared with
controls). An examination of the IDO1 expression in differ-
ent regions showed a significant increase in the hippocam-
pus, compared with the thalamus, midbrain and prefrontal
cortex (Figure 2F, P < 0.05). These results verified that the
hippocampus was a vital region for the upregulation of
IDO1 expression. We also observed that, compared with
saline treatment, 1-MT specifically inhibited IDO1 expres-
sion (Figure 3E, P < 0.01) without affecting IL-1β (Figure 3C,
P > 0.05) and IL-6 (Figure 3D, P > 0.05) expression in the
post-SE group; compared with distilled water treatment,
minocycline inhibited the expression of IDO1 (Figure 4E,
P < 0.01), IL-1β (Figure 4C, P < 0.01) and IL-6 (Figure 4D,
P < 0.01) in the post-SE group. These results showed that
IL-1β and IL-6 induced IDO1 expression.
Ratios of hippocampal tryptophan metabolites are
altered through increased IDO1 enzyme activity
To examine the role of IDO1 enzyme activity in TRY
metabolism in both the post-SE and control groups, wefirst measured TRY, 5-HT, and KYN concentrations in the
hippocampus using LC-MS and subsequently determined
the ratio of 5-HT or KYN to TRY. There were no baseline
differences in the KYN/TRY or 5-HT/TRY ratios between
the two groups (Figure 2G and H). However, at 3 and
6 weeks after SE, the KYN/TRP ratio was increased
(Figure 2G, P < 0.05 at 3 weeks after SE and P < 0.01 at
6 weeks after SE) and the 5-HT/TRP ratio was decreased
(Figure 2H, P < 0.05 at 3 weeks after SE and P < 0.01 at
6 weeks after SE) in the post-SE group compared with the
control group.
Both minocycline and 1-methyltryptophan inhibit
upregulated IDO1 expression to normalize ratios of
hippocampal tryptophan metabolites and block chronic
temporal lobe epilepsy-induced depressive-like behavior
To examine whether the inhibition of IDO1 activity in-
fluences hippocampal TRY metabolites and depressive
behaviors in epileptic rats, we administered the IDO1 in-
hibitor l-MT (50 mg/kg) or physiological saline twice
daily (at 12-hour intervals) for a period of 2 weeks, and
the treatments were administered at 8 weeks after SE.
The spontaneous seizure counts before or during 1-MT
treatment were within the same statistical range in the
two chronic TLE groups (Table 1). Treatment with 1-MT,
Figure 3 1-Methyltryptophan blocks chronic temporal lobe epilepsy-induced depressive behaviors, inhibits indoleamine 2,3-dioxygenase
expression, and normalizes tryptophan metabolites without reducing IL-1β and IL-6 expression in the hippocampus. (A) Compared with
saline treatment, the immobility time was diminished in the forced swim test (**P < 0.01 versus before treatment by paired t-test; **P < 0.01
versus saline treatment by one-way analysis of variance (ANOVA)). (B) Saccharin consumption was improved in TPT after 1-methyltryptophan
(1-MT) treatment in chronic epileptic rats (*P < 0.05 versus before treatment by paired t-test; * P < 0.05 versus saline treatment by one-way
ANOVA). (C) IL-1β and (D) IL-6 expression were unaffected by 1-MT treatment but (E) indoleamine 2,3-dioxygenase 1 (IDO1) expression was
inhibited. (F) Kynurenine (KYN)/tryptophan (TRY) and (G) serotonin (5-HT)/TRY ratios were normalized in the hippocampus of chronic epileptic
rats. Statistical significance was determined using paired t-test and one-way ANOVA. The data are presented as means ± SEM, n = 5 to 6;
*P < 0.05; **P < 0.01; n.s., not statistically significant (P > 0.05).
Figure 4 Minocycline blocks chronic temporal lobe epilepsy-induced depressive behaviors and IL-1β, IL-6 and indoleamine 2,3-dioxygenase
expression but normalizes tryptophan metabolites in the hippocampus. (A) The duration of immobility during the forced swim test was
decreased after minocycline treatment for 2 weeks in chronic epileptic rats (**P < 0.01 versus before treatment by paired t-test; **P < 0.01
versus distilled water treatment by one-way analysis of variance (ANOVA)). (B) Saccharin consumption was also improved in the TPT after
minocycline treatment (*P < 0.05 versus before treatment by paired t-test; *P < 0.05 versus distilled water treatment by one-way ANOVA). The
mRNA levels of (C) IL-1β, (D) IL-6 and (E) indoleamine 2,3-dioxygenase 1 (IDO1) were downregulated in the hippocampus after minocycline
treatment. The hippocampal (F) kynurenine (KYN)/tryptophan (TRY) and (G) serotonin (5-HT)/TRY ratios were normalized. Statistical significance was
determined using paired t-test and one-way ANOVA. The data are presented as means ± SEM, n = 5 to 6; * P < 0.05; ** P < 0.01.
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Table 1 Behavioral spontaneous seizure count in
post-status epilepticus rats























Before and during minocycline and distilled water treatments, the cumulative
spontaneous seizure count in post-status epilepticus rats over two consecutive
2-week periods indicated that no differences were observed between the two
periods for each of the groups (P > 0.05, both Wilcoxon and Mann–Whitney
tests for paired and unpaired comparisons), and across the groups (P > 0.05,
Kruskal-Wallis test). Similar results were also observed between or across the
groups (both P > 0.05) with 1-methyltryptophan (1-MT) and saline treatments.
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0.01), elevated the 5-HT/TRY ratio (Figure 3G, P < 0.05)
in the hippocampus, reduced the duration of immobility
in FST (Figure 3A, P < 0.01), and increased saccharin
consumption in TPT (Figure 3B, P < 0.05).
Similar results were obtained after treatment with the
cytokine inhibitor minocycline (100 mg/kg) or distilled
water twice daily (at 12-hour intervals) for 2 weeks
(administered at 8 weeks after SE). No significant dif-
ference in the spontaneous seizure count between the
two chronic TLE groups (Table 1) was observed, and
treatment with minocycline, but not distilled water,
also lowered the KYN/TRY ratio (Figure 4F, P < 0.01),
elevated the 5-HT/TRY ratio (Figure 4G, P < 0.01) in
the hippocampus, reduced the duration of immobility
in FST (Figure 4A, P < 0.01, and increased saccharin
consumption in TPT (Figure 4B, P < 0.05).
Consistent with the fluctuation of IDO1 expression and
depressive behavior in the post-SE group, these resultssuggest that altered ratios of TRY metabolites in the
hippocampus indicate increased IDO1 enzyme activity
in the hippocampus, which plays a key role in chronic
TLE-induced depressive behavior.
Effect of minocycline and 1-methyltryptophan inhibition
on seizures
Before and during minocycline and distilled water treat-
ments, the cumulative spontaneous seizure count in post-
SE rats over two consecutive 2-week periods indicated that
no differences were observed between the two periods
for each of the groups (Table 1, P > 0.05) and across the
groups (Table 1, P > 0.05).
Similar results were also observed between or across
the groups (Table 1, both P > 0.05) with 1-MT and saline
treatments.
Discussion
Here, we demonstrated that IL-1β, IL-6 and IDO1 expres-
sion were selectively upregulated in the hippocampus
of rats with chronic TLE and depressive behavior. The
blockade of IDO1 activation, either indirectly, with the
anti-inflammatory tetracycline derivative minocycline,
or directly, with the IDO antagonist 1-MT, prevents the
development of depressive-like behavior but failed to
affect the occurrence of spontaneous seizures. Both
minocycline and 1-MT normalize the KYN/TRY and 5-
HT/TRY ratios in the hippocampus of chronic epileptic
rats exhibiting depressive behaviors. These results indicated
that brain IDO activity plays a critical role in epileptic rats
with epilepsy-associated depressive-like behavior.
Epilepsy-associated depression has long been recognized
[1,21]. Most studies have focused on the hypothalamo-
pituitary-adrenocortical axis, monoaminergic system and
various other neurotransmitters/neuromodulators, includ-
ing GABA and brain-derived neurotrophic factor [22,23].
Despite some progress, the pathogenic mechanisms of
epilepsy-associated depression are not completely under-
stood. Although neuroinflammatory pathogenic mecha-
nisms have been identified in rats with coexisting chronic
TLE and depression [1], alteration of inflammation in the
brain has not been concluded in detail nor completely.
To our knowledge, the present study provides the first
evidence that experimental chronic TLE is accompanied
by interictal IDO upregulation and also verifies alter-
ations in hippocampal inflammation in rats with epilepsy-
associated depressive-like behavior.
The data obtained in the present study suggest a novel
mechanistic link between epilepsy and depression via
IDO1 expression in the hippocampus. The regulation of
hippocampal IDO1 expression is likely mediated through
upregulated pro-inflammatory cytokines, as the inhibition
of IDO1 activity through 1-MT treatment did not prevent
the elevation of pro-inflammatory cytokine expression,
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inhibited with minocycline treatment, which also blocks
IDO expression. The data also indicate that pro-inflamma-
tory cytokines are likely induced through chronic TLE.
These findings are consistent with previous reports that
pro-inflammatory cytokines are elevated in the hippocam-
pus of animal models [1,24-26] and patients [26,27]. In the
present study, we also observed that IDO1 was notably
upregulated in the hippocampus. These findings are con-
sistent with previous reports that certain brain regions,
including the hippocampus, play a critical role in the inte-
gration of mood changes and chronic TLE [1,28,29].
KYN and 5-HTare two major TRY metabolites produced
through the regulation of metabolic enzymes, including
IDO. The results of the present study verified that KYN/
TRY and 5-HT/TRY ratios in the hippocampus were
regulated through IDO1 activity. Increased IDO1 activity
lowers endogenous 5-HT levels; however, this activity also
increases KYN derivatives, such as QUIN, a depressogenic
glutamate receptor agonist which activates oxidative
pathways, causing mitochondrial dysfunctions, and exhibits
neuroexcitatory and neurotoxic effects that might lead to
neurodegeneration [30]. Moreover, inadequate endogenous
5-HT levels and detrimental increases in the concentration
of KYN derivatives lead to depressive symptoms [7,30,31].
Thus, IDO plays a key role in the TRY metabolic pathway,
and IDO activation modulates the level of endogenous
KYN and 5-HT, leading to epilepsy-associated depressive-
like behavior. The proposed mechanism is supported by
studies showing that blocks of IDO1 activation either
indirectly or directly normalize the increased KYN/TRY
ratio and decreased 5-HT/TRY ratio caused by IDO up-
regulation in the hippocampus. Future studies should
address the relationship between IDO expression and
other derivatives of TRY metabolism to determine the
role of this enzyme in epilepsy-associated depressive-
like behavior.
It has been previously reported that pro-inflammatory
cytokines might play an important role in epileptogen-
esis [32-34]. Considering that pro-inflammatory cyto-
kines also play a key role in the pathophysiology of
depression [30,35], verified in the present study, these
molecules might contribute to the comorbidity between
epilepsy and depression. Previous studies have indicated
that minocycline might block the epileptogenic process
[32,36] or depressive-like behaviors [37,38] through an
anti-inflammatory effect. However, in the present study,
minocycline administration did not affect spontaneous
seizures, as baseline seizure frequencies were relatively
low, which likely prohibit the modifying effects of thera-
peutic interventions. These findings are consistent with
those of previous reports [12]. The results of the present
study also suggested that the attenuation of depressive
symptoms through minocycline administration was notan epiphenomenon of the anticonvulsant effects of this
drug.
Although the observed effects of minocycline treatment
were different from the 1-MT-meadiated attenuation of
depressive symptoms, the anti-epileptic effect of this drug
was not verified in the present study. Indeed, IDO1 activa-
tion increases KYN derivatives, such as QUIN, a glutamate
receptor agonist with neuroexcitatory and neurotoxic
effects that induce epilepsy [39,40]. However, this effect
has been previously observed in the pathophysiology of
depression. Thus, IDO1 activation increases KYN deriva-
tives and likely contributes to the comorbidity between
epilepsy and depression. In the present study, 1-MT ad-
ministration attenuates depressive symptoms through the
inhibition of IDO1 activation, which normalizes KYN/
TRY and 5-HT/TRY ratios in the hippocampus. However,
1-MT did not affect spontaneous seizures, reflecting either
the relatively low baseline seizure frequencies observed in
the present study [12] or other mechanisms involved in
the described phenomenon. Notably, the experimental
protocol used in the present study might not be suitable
for the reliable examination of anti-epileptic therapies [1].
Thus, future studies will focus on effects of the TRY path-
way and 1-MT treatment on epilepsy.
In conclusion, the results of the present study impli-
cate hippocampal IDO1 activation in epilepsy-associated
depressive-like behavior, suggesting that depression in
TLE patients could be treated through the regulation
of brain inflammation and IDO1 activity. Although the
mechanism underlying the relationship between epilepsy
and depression is most likely complex and involves other
neurotransmitters and neuromodulators [16,18], the re-
sults of the present suggest a new strategy for the preven-
tion and reversal of depression in TLE patients through a
mechanism involving altered endogenous TRY metabolite
ratios via upregulated pro-inflammatory cytokines and
IDO expression in certain brain regions.
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